PharmaCyte Biotech (PMCBD) Stock Price, News & Analysis

Company Overview

PharmaCyte Biotech is a clinical‐stage biotechnology company focused on the development and commercialization of targeted cellular therapies for cancer and diabetes. The company’s core technology, Cell-in-a-Box, encapsulates live, genetically modified cells within a proprietary cellulose‐based polymer matrix. This platform is designed to deliver therapeutic agents directly at tumor sites or within the pancreas, with the goal of maximizing efficacy while minimizing systemic side effects.

In its lead oncology program, PharmaCyte is conducting clinical trials for advanced pancreatic cancer, combining Cell-in-a-Box–encased cells with the prodrug ifosfamide. The encapsulated cells convert ifosfamide into its active form at the tumor site, potentially improving survival outcomes and quality of life for patients. In parallel, the company is advancing a preclinical diabetes therapy that employs encapsulated insulin-producing cells, seeking to offer an alternative to daily insulin injections for people with type 1 diabetes.

Founded in the mid-1990s and rebranded as PharmaCyte Biotech in 2008, the company has established research and manufacturing collaborations in the United States and Europe. Its development work adheres to Good Manufacturing Practice (GMP) standards at partner facilities, and its pipeline reflects a strategic emphasis on diseases with significant unmet medical needs. PharmaCyte’s management team brings together expertise in biotechnology, clinical development and regulatory affairs as the company moves its lead programs through pivotal stages toward potential commercialization.

Key Stats

• Today's Range: $0.54 to $0.58
• 50-Day Range: $0.55 to $0.83
• 52-Week Range: $5.56 to $55.50
• Volume: 66,506 shs
• Average Volume: 8,831 shs
• Market Capitalization: $919.05 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:PMCBD
• CIK: N/A
• Web: www.pharmacyte.com
• Phone: (917) 595-2850
• Fax: N/A
• Employees: N/A
• Year Founded: 1996

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.83 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -49.09%
• Return on Assets: -43.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.90
• Quick Ratio: 4.90

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 1,671,000
• Free Float: N/A
• Market Cap: $919.05 thousand
• Optionable: Not Optionable
• Beta: 0.27